University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
David V. Glidden, PhD

David V. Glidden, PhD

Professor of Biostatistics, UCSF

Research Summary

My work focuses on the prevention and treatment of HIV infection.

I have been involved in studies of HIV prevention (specifically, truvada for PrEP) for over 12 years. I was the statistician for the iPrEx trial -- the first trial to report the efficacy of oral PrEP and worked on the drugs approval by the FDA. My current work involves studies of the global scale-up of PrEP, innovative designs/statistical analyses of new PrEP agents, and pharmacologic markers of PrEP exposure.

I also collaborate on studies on the outcomes of HIV treatment in resource limited settings. In these settings many patients are absent from clinics. This data requires handling several statistical issues including clustering, competing risk/multiple outcomes, time-dependent covariates and informative censoring. My colleagues and I have pioneered sampling based approaches to losses to follow-up which have given rigorous information about treatment outcomes.

I also collaborate for groups in neurology, pediatrics, LGBT health and nephrology and teach in my department's MCR and Ph.D. program.

Education

University of California, Berkeley, CA, BA, 1988, Statistics
University of Washington, Seattle, WA, PhD, 1993, Biostatistics
Harvard University, Boston, MA, Fellowship, 1995, Biostatistics


Professional Experience

  • 1988 - 1993
    University of Washington Research Assistant
  • 1993 - 1995
    Harvard University Research Fellow
  • 1995 - 1997
    Harvard University Research Associate
  • 1997 - 2003
    University of California, San Francisco Assistant Adjunct Professor
  • 2003 - 2007
    University of California, San Francisco Associate Professor in Residence
  • 2007 -
    University of California, San Francisco Professor in Residence

Honors & Awards

  • 1988
    W.W. Stout Fellowship, Graduate School, University of Washington
  • 1988 - 1990
    Graduate Fellowship Award, Graduate School, University of Washington
  • 1990 - 1993
    National Research Service Award, National Heart, Lung and Blood Institute
  • 1993
    School of Public Health Outstanding Student Citation for Biostatistics, Univ. of Washington
  • 2007
    TICR Award for Excellence in Teaching

Selected Publications

  1. Schnarrs PW, Gordon D, Martin-Valenzuela R, Sunil T, Delgado AJ, Glidden D, Parsons JT, McAdams J. Perceived Social Norms About Oral PrEP Use: Differences Between African-American, Latino and White Gay, Bisexual and Other Men Who Have Sex with Men in Texas. AIDS Behav. 2018 Nov; 22(11):3588-3602.
    View on PubMed
  2. Geng EH, Glidden DV, Padian N. Strengthening HIV-prevention trials: a dose of implementation science? Lancet Infect Dis. 2018 Nov; 18(11):1166-1168.
    View on PubMed
  3. Liu KD, Yang J, Tan TC, Glidden DV, Zheng S, Pravoverov L, Hsu CY, Go AS. Risk Factors for Recurrent Acute Kidney Injury in a Large Population-Based Cohort. Am J Kidney Dis. 2018 Oct 10.
    View on PubMed
  4. Jotwani V, Scherzer R, Glidden DV, Mehrotra M, Defechereux P, Liu A, Gandhi M, Bennett M, Coca SG, Parikh CR, Grant RM, Shlipak MG. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals. J Acquir Immune Defic Syndr. 2018 Jun 01; 78(2):169-174.
    View on PubMed
  5. Dunn DT, Glidden DV, Stirrup OT, McCormack S. The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents. Lancet HIV. 2018 Jun; 5(6):e329-e334.
    View on PubMed
  6. Mehrotra ML, Rivet Amico K, McMahan V, Glidden DV, Defechereux P, Guanira JV, Grant RM. The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men. AIDS Behav. 2018 May 12.
    View on PubMed
  7. Roy M, Holmes C, Sikazwe I, Savory T, Mwanza MW, Bolton Moore C, Mulenga K, Czaicki N, Glidden DV, Padian N, Geng E. Application of a multi-state model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of HIV Treatment in Zambia. Clin Infect Dis. 2018 Apr 07.
    View on PubMed
  8. Meyers K, Wu Y, Qian H, Sandfort T, Huang X, Xu J, Zhang J, Xia W, Glidden D, Wu H, Shang H. Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China. AIDS Behav. 2018 Apr; 22(4):1217-1227.
    View on PubMed
  9. Hojilla JC, Vlahov D, Glidden DV, Amico KR, Mehrotra M, Hance R, Grant RM, Carrico AW. Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis. J Int AIDS Soc. 2018 Mar; 21(3):e25103.
    View on PubMed
  10. Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM. Metabolic Effects of Pre-Exposure Prophylaxis with Co-Formulated Tenofovir Disoproxal Fumarate and Emtricitabine. Clin Infect Dis. 2018 Feb 03.
    View on PubMed
  11. Holmes CB, Sikazwe I, Sikombe K, Eshun-Wilson I, Czaicki N, Beres LK, Mukamba N, Simbeza S, Bolton Moore C, Hantuba C, Mwaba P, Phiri C, Padian N, Glidden DV, Geng E. Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey. PLoS Med. 2018 Jan; 15(1):e1002489.
    View on PubMed
  12. Hojilla JC, Mehrotra M, Truong HM, Glidden DV, Amico KR, McMahan V, Vlahov D, Chariyalertsak S, Guanira JV, Grant RM. HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis. AIDS Care. 2018 Apr; 30(4):466-472.
    View on PubMed
  13. Cutrell A, Donnell D, Dunn DT, Glidden DV, Grobler A, Hanscom B, Stancil BS, Meyer RD, Wang R, Cuffe RL. HIV prevention trial design in an era of effective pre-exposure prophylaxis. HIV Clin Trials. 2017 Nov-Dec; 18(5-6):177-188.
    View on PubMed
  14. Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. J Acquir Immune Defic Syndr. 2017 10 01; 76(2):177-182.
    View on PubMed
  15. Semeere A, Freeman E, Wenger M, Glidden D, Bwana M, Kanyesigye M, Asirwa FC, Rotich E, Busakhala N, Oga E, Jedy-Agba E, Kwaghe V, Iregbu K, Adebamowo C, Jaquet A, Dabis F, Phiri S, Bohlius J, Egger M, Yiannoutsos CT, Wools-Kaloustian K, Martin J. Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa. BMC Cancer. 2017 Sep 02; 17(1):611.
    View on PubMed
  16. Perito ER, Ajmera V, Bass NM, Rosenthal P, Lavine JE, Schwimmer JB, Yates KP, Diehl AM, Molleston JP, Murray KF, Scheimann A, Gill R, Glidden D, Aouizerat B. Association Between Cytokines and Liver Histology in Children with Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2017 Sep; 1(7):609-622.
    View on PubMed
  17. Bershetyn A, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, Kambugu A, Bukusi E, Hartogensis W, Glidden DV, Wools-Kaloustian K, Yiannoutsos C, Martin J, Geng EH. The Causal Effect of Tracing by Peer Health Workers on Return to Clinic Among Patients Who Were Lost to Follow-up From Antiretroviral Therapy in Eastern Africa: A "Natural Experiment" Arising From Surveillance of Lost Patients. Clin Infect Dis. 2017 Jun 01; 64(11):1547-1554.
    View on PubMed
  18. Glidden DV, Mayer K, Grant RM. Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to Treponema pallidum? Sex Transm Infect. 2017 08; 93(5):313.
    View on PubMed
  19. Rushakoff RJ, Sullivan MM, MacMaster HW, Shah AD, Rajkomar A, Glidden DV, Kohn MA. Association Between a Virtual Glucose Management Service and Glycemic Control in Hospitalized Adult Patients: An Observational Study. Ann Intern Med. 2017 May 02; 166(9):621-627.
    View on PubMed
  20. Christopoulos KA, Hartogensis W, Glidden DV, Pilcher CD, Gandhi M, Geng EH. Limitations of using the Lorenz curve framework to understand the distribution of population viral load: authors' reply. AIDS. 2017 Mar 13; 31(5):742-743.
    View on PubMed

Go to UCSF Profiles, powered by CTSI